Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cytarabine + Daunoxome + Fludarabine + Methotrexate
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cytarabine Cytosar-U Ara-C Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).
Daunoxome Liposomal daunorubicin citrate Chemotherapy - Anthracycline 13 Daunoxome is a liposomal formulation of the anthracyline, daunorubicin and is FDA approved for HIV-associated Kaposi’s sarcoma (FDA.gov).
Fludarabine Fludara FAMP|Fludarabine phosphate Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)
Methotrexate Abitrexate Amethopterin Chemotherapy - Antimetabolite 14 Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03643276 Phase III Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Mercaptopurine + Methotrexate Bortezomib + Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Pegaspargase + Vincristine Sulfate + Vindesine Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab Cytarabine + Daunoxome + Fludarabine + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate Asparaginase Erwinia chrysanthemi Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting ITA | DEU | AUT | AUS 4


Additional content available in CKB BOOST